Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $272.89 Consensus PT from Analysts

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been assigned an average rating of “Buy” from the eighteen research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $285.4444.

JAZZ has been the subject of several recent research reports. Raymond James Financial reissued an “outperform” rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft raised their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a report on Tuesday, August 4th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $264.00 to $281.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a research report on Wednesday.

Jazz Pharmaceuticals Stock Down 2.6%

JAZZ opened at $244.54 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The company has a market capitalization of $15.88 billion, a PE ratio of 16.86, a P/E/G ratio of 0.23 and a beta of 0.32. The stock’s fifty day moving average is $247.30 and its 200-day moving average is $218.31. Jazz Pharmaceuticals has a one year low of $123.88 and a one year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company’s quarterly revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($8.25) EPS. On average, equities analysts predict that Jazz Pharmaceuticals will post 21.51 EPS for the current fiscal year.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Higher analyst price targets support the bullish case. Truist raised its JAZZ price target to $281, while Needham and other analysts highlighted the potential for further appreciation. The positive views likely reflect Jazz’s earnings power, specialty-pharmaceutical portfolio and recent revenue growth. Truist Financial Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz is pairing its debt issuance with share repurchases. The company priced an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032, up from $1 billion, while announcing concurrent ordinary-share buybacks. The low coupon and repurchases could support capital flexibility and per-share results, although exchangeability creates potential future dilution. Jazz Pharmaceuticals Announces Pricing of Exchangeable Senior Notes
• Positive Sentiment: Roche’s expanded FDA approval for a diagnostic linked to a Jazz cancer medicine may broaden patient identification and market access. The development could help physicians identify appropriate patients for the associated therapy, although the commercial benefit to Jazz depends on adoption and the economics of the diagnostic relationship. Roche Receives Expanded FDA Approval for Diagnostic
• Neutral Sentiment: Jazz’s oncology outlook is being reassessed after Ziihera received first-line approval for HER2-positive gastroesophageal cancer. The approval could increase competition in a key oncology setting, but it also underscores the importance of Jazz’s broader oncology pipeline and product positioning. Ziihera First-Line HER2-Positive GEA Approval
• Negative Sentiment: Zacks Research cut several forward EPS estimates. Its FY2026 forecast fell to $20.77 from $21.72, FY2027 to $20.02 from $22.26, and estimates for multiple quarterly periods were also reduced. Although FY2028 EPS was left broadly stable at $22.74, the near- and medium-term downgrades may pressure sentiment and suggest investors are monitoring growth and execution risks.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Mark Douglas Smith sold 1,157 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $230.55, for a total transaction of $266,746.35. Following the sale, the director owned 9,680 shares in the company, valued at approximately $2,231,724. The trade was a 10.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the sale, the director directly owned 360,682 shares of the company’s stock, valued at $91,245,332.36. This represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 14,357 shares of company stock valued at $3,505,642. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $25,000. Ameritas Advisory Services LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter worth $47,000. LRI Investments LLC acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $38,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at $61,000. Finally, Westpac Banking Corp purchased a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $51,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.